KORU: Clinical Hype Fails to Justify 16% Overvaluation
By stockpickr AI | March 1, 2026 | 10 min read
Investment Summary
KORU is a high-risk clinical-stage biopharma stock currently trading below book value, with valuation heavily dependent on future clinical trial results.
Investment Recommendation
Hold
Fair Value: $3.50
Current Price: $4.18
Upside/Downside: -16.27%
The DCF model is highly speculative due to negative or zero revenue currently; valuation is based purely on terminal value and requires significant future growth assumptions.
Key Metrics
- No metrics available